| Pilot Study of Casdatifan-Treated Refractory Renal Cell Carcinoma (NCT07748988) | Vanderbilt-Ingram Cancer Center | 2029-07-01 |
| Lazarus: IT Therapy for ICANS (NCT07763210) | Vanderbilt-Ingram Cancer Center | 2026-10-01 |
| Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC) (NCT07741565) | Vanderbilt-Ingram Cancer Center | 2026-09-30 |
| Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma (NCT07741643) | Vanderbilt-Ingram Cancer Center | 2026-08-01 |
| Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma (NCT07673367) | Vanderbilt-Ingram Cancer Center | 2026-07-31 |
| Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) (NCT07460765) | Vanderbilt-Ingram Cancer Center | 2026-07-01 |
| Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma (NCT07217028) | Vanderbilt-Ingram Cancer Center | 2026-04-24 |
| Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy (NCT06828588) | Vanderbilt-Ingram Cancer Center | 2026-04-16 |
| Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer (NCT06819228) | Vanderbilt-Ingram Cancer Center | 2025-04-17 |
| Biomarker Platform (Virtual Nodule Clinic) for the Management of Indeterminate Pulmonary Nodules (NCT06638398) | Vanderbilt-Ingram Cancer Center | 2024-10-31 |
| Cryodevitalization for the Treatment of Early Stage Lung Cancer, CRYSTAL Trial (NCT06593106) | Vanderbilt-Ingram Cancer Center | 2024-09-27 |
| EBUS-TBNA vs Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing (NCT06105801) | Vanderbilt-Ingram Cancer Center | 2024-09-13 |
| Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia (NCT06399640) | Vanderbilt-Ingram Cancer Center | 2024-08-14 |
| Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors (NCT06016855) | Vanderbilt-Ingram Cancer Center | 2024-05-31 |
| Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers (NCT05919108) | Vanderbilt-Ingram Cancer Center | 2024-05-30 |
| Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation (NCT06110572) | Vanderbilt-Ingram Cancer Center | 2024-04-24 |
| A Combined Biomarker Model for Risk Stratification of Indeterminate Pulmonary Nodules (NCT06074133) | Vanderbilt-Ingram Cancer Center | 2024-03-07 |
| Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer (NCT06140407) | Vanderbilt-Ingram Cancer Center | 2024-02-14 |
| Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer (NCT05945875) | Vanderbilt-Ingram Cancer Center | 2023-10-03 |
| Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy (NCT05770531) | Vanderbilt-Ingram Cancer Center | 2023-10-03 |
| Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy (NCT05996432) | Vanderbilt-Ingram Cancer Center | 2023-05-17 |
| Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer (NCT05501665) | Vanderbilt-Ingram Cancer Center | 2023-05-09 |
| Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors (NCT05764395) | Vanderbilt-Ingram Cancer Center | 2023-05-09 |
| Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study (NCT05361720) | Vanderbilt-Ingram Cancer Center | 2022-12-06 |
| Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor (NCT04454476) | Vanderbilt-Ingram Cancer Center | 2022-11-09 |
| Improving Care After Inherited Cancer Testing (NCT04763915) | Vanderbilt-Ingram Cancer Center | 2022-08-05 |
| Cohort to Augment the Understanding of Sarcoma Survivorship Across the Lifespan (NCT06482957) | Vanderbilt-Ingram Cancer Center | 2022-04-01 |
| Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting (NCT05108805) | Vanderbilt-Ingram Cancer Center | 2021-12-02 |
| Impact of Human-Animal Interactions on Children With Life-Threatening Conditions and Their Parents (NCT04310345) | Vanderbilt-Ingram Cancer Center | 2021-03-31 |
| Hypofractionated Radiotherapy Followed by Surgical Resection in the Treatment of Soft Tissue Sarcomas (NCT04506008) | Vanderbilt-Ingram Cancer Center | 2021-03-02 |
| Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer (NCT04883827) | Vanderbilt-Ingram Cancer Center | 2021-01-06 |
| Metabolism Informed Smoking Treatment: The MIST RCT (NCT04590404) | Vanderbilt-Ingram Cancer Center | 2020-11-17 |
| The Clonal Hematopoiesis & Inflammation in Vasculature Registry and Biorepository (NCT06701214) | Vanderbilt-Ingram Cancer Center | 2020-10-28 |
| Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System (NCT04327999) | Vanderbilt-Ingram Cancer Center | 2020-10-05 |
| Navigation Endoscopy to Reach Indeterminate Lung Nodules Versus Trans-Thoracic Needle Aspiration (NCT04250194) | Vanderbilt-Ingram Cancer Center | 2020-05-22 |
| COVID-19 and Cancer Consortium Registry (NCT04354701) | Vanderbilt-Ingram Cancer Center | 2020-03-17 |
| Assessing Benefits of NIRAF Detection for Identifying Parathyroid Glands During Total Thyroidectomy. (NCT04281875) | Vanderbilt-Ingram Cancer Center | 2020-03-16 |
| Evaluating Impact of NIRAF Detection for Identifying Parathyroid Glands During Parathyroidectomy (NCT04299425) | Vanderbilt-Ingram Cancer Center | 2020-03-13 |
| Central Pain Syndrome in Survivors of Head and Neck Cancer (NCT04128267) | Vanderbilt-Ingram Cancer Center | 2019-11-04 |
| Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency (NCT04073017) | Vanderbilt-Ingram Cancer Center | 2019-11-04 |
| ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia (NCT04013880) | Vanderbilt-Ingram Cancer Center | 2019-08-27 |
| Yoga Intervention in Supporting Children With Cancer and Their Parents During Chemotherapy Infusion (NCT04034914) | Vanderbilt-Ingram Cancer Center | 2019-08-07 |
| A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer (NCT03962647) | Vanderbilt-Ingram Cancer Center | 2019-07-08 |
| Finding the Cause for Post-Transplant Diabetes Mellitus After Allogeneic Hematopoietic Cell Transplant (NCT03415139) | Vanderbilt-Ingram Cancer Center | 2019-03-12 |
| Animal-Assisted Interactions in Children With Life-Threatening Conditions and Their Parents (NCT03765099) | Vanderbilt-Ingram Cancer Center | 2019-02-21 |
| Studying Health Outcomes After Treatment in Patients With Retinoblastoma (NCT03932786) | Vanderbilt-Ingram Cancer Center | 2019-01-24 |
| Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (NCT03652233) | Vanderbilt-Ingram Cancer Center | 2018-11-02 |
| Tumor-Treating Fields Therapy in Preventing Brain Tumors in Participants With Extensive-Stage Small Cell Lung Cancer (NCT03607682) | Vanderbilt-Ingram Cancer Center | 2018-09-05 |
| Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors (NCT03583086) | Vanderbilt-Ingram Cancer Center | 2018-07-10 |
| Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer (NCT03566485) | Vanderbilt-Ingram Cancer Center | 2018-07-10 |
| Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma (NCT03558750) | Vanderbilt-Ingram Cancer Center | 2018-06-14 |
| PET Imaging of Ovarian Carcinoma With 18F-FSPG (NCT02872519) | Vanderbilt-Ingram Cancer Center | 2018-06-01 |
| Bronchoscopy With Bronchoalveolar Lavage in Identifying Biomarkers of Response to Immune Checkpoint Inhibitors in Patients With Non-small Cell or Small Cell Lung Cancer (NCT02937402) | Vanderbilt-Ingram Cancer Center | 2018-04-05 |
| Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads (NCT03023904) | Vanderbilt-Ingram Cancer Center | 2017-12-29 |
| Early Detection of Lung Cancer (NCT03181256) | Vanderbilt-Ingram Cancer Center | 2017-12-14 |
| Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor (NCT02831179) | Vanderbilt-Ingram Cancer Center | 2017-12-01 |
| High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients (NCT03179761) | Vanderbilt-Ingram Cancer Center | 2017-10-09 |
| Circulating Blood Profile to Predict Recurrence and Response to Systemic Therapy (NCT03267381) | Vanderbilt-Ingram Cancer Center | 2017-10-03 |